Fort Myers-based cancer testing and research lab NeoGenomics expects to report double-digit revenue growth for 2025. However, ...

Lab is located in same building as PPD® Laboratories’ Central Lab and will support Asia-Pacific oncology trials Fully integrated with PPD’s CRO capabilities, PPD Laboratories offers bioanalytical, ...

Anticipates preliminary unaudited fourth quarter 2025 revenue of approximately $190 million; full-year 2025 revenue of $727 ...

NeoGenomics appointed Abhishek Jain to the role of chief financial officer, succeeding Jeff Sherman, who is set to retire from the position in March.

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran ...

FT. MYERS, Fla., Oct. 23, 2018 (GLOBE NEWSWIRE) — NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has entered into a definitive ...

WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), and NeoGenomics Laboratories, Inc., a leading provider of ...

This time it's going to China. The Fort Myers-based laboratory — specializing in genetic testing for cancer — has announced plans to grow its global footprint with the addition of a research lab in ...

FORT MYERS, FL / ACCESSWIRE / October 13, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced plans to open a ...